Amicus Therapeutics (NASDAQ: FOLD) reported Q2 EPS of $0.06, $0.11 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $126.67 million versus the consensus estimate of $121.21 million.

Total Revenue Growth: 25% to 30% → 26% to 31%
Galafold Revenue Growth: 13% to 17% → 14% to 18%
Pombiliti + Opfolda Revenue: $62M to $67M → $62M to $67M
Non-GAAP Operating Expense: $345M to $365M → $345M to $360M

For earnings history and earnings-related data on Amicus Therapeutics (FOLD) click here.